No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Jinghua Pharmaceutical Group (SZSE:002349) Shareholders Are Still up 91% Over 5 Years Despite Pulling Back 5.4% in the Past Week
Jinghua Pharmaceutical Group Co., Ltd.'s (SZSE:002349) Share Price Is Matching Sentiment Around Its Earnings
Essence Pharmaceuticals: Report for the third quarter of 2024
jinghua pharmaceutical group (002349.SZ) released its performance for the first three quarters, with a net income of 0.164 billion yuan, a year-on-year decrease of 15.93%.
jinghua pharmaceutical group (002349.SZ) released the quarterly report for the third quarter of 2024. In the first three quarters, the company achieved revenue...
We Think Jinghua Pharmaceutical Group (SZSE:002349) Can Manage Its Debt With Ease
